Oregon woman dies from rare blood clot after Johnson & Johnson vaccine, CDC investigating –

Sorry, Readability was unable to parse this page for content.


Oregon woman dies from rare blood clot after Johnson & Johnson vaccine, CDC investigating –

Sorry, Readability was unable to parse this page for content.


Oregon woman dies from rare blood clot after Johnson & Johnson vaccine, CDC investigating –

Sorry, Readability was unable to parse this page for content.


Oregon woman dies from rare blood clot after Johnson & Johnson vaccine, CDC investigating –

Sorry, Readability was unable to parse this page for content.


Oxford Malaria vaccine proves highly effective in Burkina Faso trial – The Guardian


Vaccine developed by scientists at Jenner Institute, Oxford, shows up to 77% efficacy in trial over 12 months

Fri 23 Apr 2021 05.01 BST

A vaccine against malaria has been shown to be highly effective in trials in Africa, holding out the real possibility of slashing the death toll of a disease that kills 400,000 mostly small children every year.

The vaccine, developed by scientists at the Jenner Institute of Oxford University, showed up to 77% efficacy in a trial of 450 children in Burkina Faso over 12 months.

The hunt for a malaria vaccine has been going on the best part of a century. One, the Mosquirix vaccine developed by GlaxoSmithKline, has been through lengthy clinical trials but is only partially effective, preventing 39% of malaria cases and 29% of severe malaria cases among small children in Africa over four years. It is being piloted by the World Health Organization in parts of Kenya, Ghana and Malawi.

The Oxford vaccine is the first to meet the WHO goal of 75% efficacy against the mosquito-borne parasite disease. Larger trials are now beginning, involving 4,800 children in four countries.

Prof Adrian Hill, director of the Jenner Institute, where the Oxford/AstraZeneca Covid vaccine was invented, said he believed the vaccine had the potential to cut the death toll dramatically. “What we’re hoping to do is take that 400,000 down to tens of thousands in the next five years, which would be absolutely fantastic.”

Other interventions, such as impregnated bednets and malarial drugs, have reduced the death toll from a million a year, he said, and those must continue. But, if the vaccine could cut deaths to the tens of thousands, they might be able to look towards “a greater goal – eventually eradicating malaria”.

Hill said the institute might apply for emergency approval for the malaria vaccine just as it did for the Covid jab. “I’m making the argument as forcefully as I can, that because malaria kills a lot more people than Covid in Africa, you should think about emergency-use authorisation for a malaria vaccine for use in Africa. And that’s never been done before.”

The institute would probably ask the regulatory bodies in Europe or the UK for a scientific opinion on the vaccine and then apply to the World Health Organization for approval for use in Africa. “They did Covid in months – why shouldn’t they do malaria in a similar length of time as the health problem is an even greater scale in Africa?” Hill said.

The vaccine will be manufactured at large scale and low-cost, say the researchers, who have arranged a deal with the Serum Institute of India, which is involved in manufacturing the Oxford/AstraZeneca Covid-19 vaccine.

The Serum Institute has had to delay supplies of the Covid vaccine to the rest of the world because of the huge rise in cases in India, but has promised to deliver 200m doses a year of the malaria vaccine if it is licensed.

Hill said the best-case scenario was approval by the end of 2022, by which time the Serum Institute would have plenty of capacity.

Dr Cyrus Poonawalla and Adar Poonawalla, respectively chair and CEO of the Serum Institute, said in a statement that they were “highly excited to see these results on a safe and highly effective malaria vaccine which will be available to the whole world”. The project was through collaboration with Oxford and also Novavax, which is supplying the adjuvant, a substance that enhances the immune system response.

“We are highly confident that we will be able to deliver more than 200m doses annually in line with the strategy, as soon as regulatory approvals are available,” they said.

The children in the trial, which is published in the Lancet journal, were five to 17 months old and lived in Nanoro, an area encompassing 24 villages with an approximate population of 65,000 people. They were split into three groups; two had the vaccine, but with either a low or high dose of adjuvant, while the third group were given a rabies vaccine, so acted as a control.

The children had three doses and have since had a further booster jab. The Mosquirix vaccine is also given as four doses.

Hill said mothers were keen to bring their children back for further shots because of their experience of malaria. Efficacy was 77% in the high-dose adjuvant group and 74% in the lower dose group.

Gareth Jenkins, of Malaria No More UK, said: “We can end malaria in our generation but only if governments invest in the research needed to deliver the new medicines and products that can accelerate the end of this terrible disease.

“The Jenner Institute’s groundbreaking work on both the new Covid-19 and malaria vaccines is a great example of this and demonstrates just how much humanity’s safety is dependent on new science.

“An effective and safe malaria vaccine would be a hugely significant extra weapon in the armoury needed to defeat malaria, which still kills over 270,000 children every year. For decades British scientists have been at the forefront of developing new ways to detect, diagnose, test and treat malaria, and we must continue to back them.

“A world without malaria is a world safer both for the children who would otherwise be killed by this disease, and for us here at home. Countries freed from the malaria burden will be much better equipped to fight off new disease threats when they inevitably emerge in the future.”












We will be in touch to remind you to contribute. Look out for a message in your inbox in June 2021. If you have any questions about contributing, please contact us.

Medics at Iowa state prison gave 77 inmates up to SIX TIMES the normal dose of the Pfizer vaccine – Daily Mail

Dozens of inmates at an Iowa state prison were given overdoses of coronavirus vaccines, according to the Iowa Department of Corrections (DOC).

On Tuesday, two medical staffers gave 77 prisoners at the Iowa State Penitentiary up to three milliliters (mL) of the Pfizer-BioNTech COVID-19, the department told the Des Moines Register.

This is six times higher than the dose of 0.5 mL they should have received.   

Cord Overton, a spokesperson for the DOC, said none of the inmates affected by the error have experienced side effects but have not fallen ill enough to require hospitalization. 

Medical staff gave 77 inmates at the Iowa State Penitentiary (pictured) were given the wrong dose of the Pfizer-BioNTech coronavirus vaccine

Medical staff gave 77 inmates at the Iowa State Penitentiary (pictured) were given the wrong dose of the Pfizer-BioNTech coronavirus vaccine

Medical staff gave 77 inmates at the Iowa State Penitentiary (pictured) were given the wrong dose of the Pfizer-BioNTech coronavirus vaccine

Patients were given 3 mL doses, which is six times higher than the dose of 0.5 mL they should have received

Patients were given 3 mL doses, which is six times higher than the dose of 0.5 mL they should have received

Patients were given 3 mL doses, which is six times higher than the dose of 0.5 mL they should have received

After learning that the error had been committed, DOC said it contacted the Centers for Disease Control and Prevention (CDC) for guidance. 

Federal health officials said they did not expect any of the inmates to have severe reactions, but recommended they be monitored for 48 hours.

The inmates given the higher-than recommended doses have been notified and are being monitored by the prison’s medical staff. 

According to Overton, the only symptoms the prisoners appear to be experiencing are those commonly associated with the vaccine.

‘The large majority of inmates continue to have very minor symptoms consistent with those that receive the recommended dose of the vaccine,’ he told the Register.  

‘These include sore arm, body aches, and one inmate has experienced a low-grade fever, which was treatable with Tylenol.’   

Dr Peter Chin-Hong, a professor of medicine and infectious disease specialist at the University of California, San Francisco, said that during clinical trials, those who received higher doses were more likely to experience side effects.

‘The higher dose you get, the higher chance of getting local reactions and systemic  events,’ he told

‘Every single measure, a higher chance of fatigue, fever, chills muscle pain, joint pain. No serious side effects beyond what we know about, just a higher chance of receiving side effects.’ 

The Iowa DOC is currently not administering doses of the vaccine at the maximum-security prison while an investigation is conducted.

Overton said the two staff members who made the error have been placed on administrative leave for the time being.  

Neither the Iowa DOC nor Pfizer returned’s request for comment in time for publication. 

The prison insists the wrongly administered doses were accidental – and there is no evidence to suggest this was an experiment.

But word of prisoners given an overdose of vaccine hardly encourages trust in the vaccinators, especially in a disadvantaged population of prisoners. 

Already, about 20 percent of Americans are vaccine hesitant.  

Rates are of hesitancy are highest among communities of color – who are incarcerated at up to five times the rate of white Americans –  who are wary of getting vaccines due to past racist health policies that preyed on minorities. 

One of the most well-known examples is the Tuskegee experiments from 1932 to 1971, in which black men were used to track the progression of syphilis.

However, the study was run without their consent and they never received treatment to cure the sexually transmitted infection. 

‘If you think historically for African Americans in the U.S. in terms of what the history has been with respect to their interaction with the healthcare system, of course we know the Tuskegee study,’ Dr Diana Grigsby-Toussaint, an associate professor in the department behavioral and social sciences an the department of epidemiology as the Brown University School of Public Health told Healthline.

‘Tuskegee was not that long ago. The last surviving member died in 2004. It’s not something that is far removed. It’s still in people’s memory.


Pierce County facing reality of possible roll back to Phase 1 – KIRO Seattle

PIERCE COUNTY, Wash. — Whether or not a customer at Azure Cafe wants sugar or milk with their order, every cup of coffee Tracy Roberts brews is bittersweet.

“It’s exciting to see those people, but it’s also sad,” said Roberts, owner of Cafe Azure. “I had somebody come in last week and they were like, ‘Oh my gosh, how old’s the baby now?’ I was like, ‘She’s nine months old.’ I haven’t seen that person since I was pregnant. Things like that make you realize, ‘Wow, it’s been a long time.’”

A few months before Roberts gave birth last July, she opened up Azure Cafe in downtown Tacoma. A major reason why she chose to open her shop on Market Street was the potential for high volumes of pedestrians.

“Foot traffic is like virtually nothing now,” she said. “We’re barely hanging as it is.”

“It could go back”

Business owners and health officials in Tacoma and Pierce County are facing a potential, harsh reality: a rollback into Phase 1, which includes a ban on indoor dining.

“It could go back to a level that we saw at the turn of the year, in which case, absolutely we’d be going back to Phase 1,” said Nigel Turner, Tacoma-Pierce County Health Department director of communicable disease.

A rollback to Phase 1 hinges on the county’s 14-day case rate per 100,000 people. “The 14-day case rate offers the most reliable look at COVID-19 disease burden on Pierce County,” the county health department states on its website.

As of Wednesday, Pierce County’s case rate was 211.6. The phase a county is in depends on the rate: Phase 3 includes counties with a case rate of less than 200, Phase 2 includes counties with case rates between 200 and 350, and Phase 1 includes counties with case rates higher than 350.

Turner said the reason why Pierce County is seeing higher case rates than neighboring counties is due to younger people not following guidelines, like wearing masks or social distancing.

“There’s nothing specifically new here,” Turner said, emphasizing that younger populations have been driving up case rates in the county for months. “It’s just too soon to let down our guard.”

“Phase Done”

While Pierce County faces the possibilty of rolling back to Phase 1, one business in Tacoma is ready for “Phase Done.”

Kyle Bidwell, owner of An American Tavern in Tacoma, plans to appeal a fine from the Washington State Liquor and Cannabis Board. A spokesperson with LCB stated the agency issued two citations and two warnings to the bar last year. Those offenses led to “a Board decision of $500 fine of 5-day suspension on 4/13/2021.

“We are currently investigating 17 complaints from last weekend,” the spokesperson wrote in an email on Wednesday.

Bidwell said in a phone interview that the claims against his business are untrue.

“It’s the people that are never in my tavern making up these claims,” he said. “My hours have been cut dramatically. We’re following 25% capacity.”

Bidwell also believes the statewide COVID-19 restrictions are “a violation of our constitutional rights.”

“People have a right to work and businesses have a right to operate. Inslee is destroying people’s lives,” Bidwell said, while pointing to states like Florida. “Inslee wants our bars to close and he’s trying to make that happen.”

“Leading the way, unforunately”

While Pierce County is the largest county of the three to roll back to Phase 2, neighboring states are facing similar dilemmas as cases and hospitalizations begin to rise.

“COVID is circulating very much in our area and is increasing,” said Dr. Chris Spitters, health officer for Snohomish County, on Tuesday.

Spitters said current case and hospitalization rates have put Snohomish County in serious jeopardy of sliding back to Phase 2. He also said a rollback to Phase 1 would likely follow if measures weren’t taken to slow down cases.

“Case rates overall in Washington are catching up behind us, sadly,” Turner said. “So it’s something we’re in together.”

“One more shot”

As Roberts contemplated the possibility of shutting down her 1-year-old business again, a familiar face walked into the door: Jody Eveler, a regular customer who across the street works for the City of Tacoma.

“Hi, how are you doing?” Roberts said to Eveler with a smile hiding behind her mask.

“I try every time that I’m here to come over and support the business here because I know she’s struggling so bad,” Eveler said.

With COVID-19 restrictions still in place, Eveler only works at her downtown office occasionally. But when she does, she makes sure to stop by Azure Cafe.

“I find it heartbreaking,” Eveler said about the possibility of rolling back to Phase 1. “I just don’t know how these businesses are surviving.”

Roberts isn’t sure, either. She admits she’s only been able to keep her business open thanks to an understanding property owner. “If he wasn’t so generous, we wouldn’t be here by any means,” she said. “I’m all for keeping everyone safe, but at some point, our economy has to be a factor. But regardless of how I feel personally as a business owner, I’m going to do what I need to do to keep my business alive, and keep my customers and myself safe.”


Oregon woman dies from rare blood clot after Johnson & Johnson vaccine, CDC investigating –

Sorry, Readability was unable to parse this page for content.


People With Severe COVID-19 Have Higher Risk Of Long-Term Effects, Study Finds – NPR

NPR’s sites use cookies, similar tracking and storage technologies, and information about the device you use to access our sites (together, “cookies”) to enhance your viewing, listening and user experience, personalize content, personalize messages from NPR’s sponsors, provide social media features, and analyze NPR’s traffic. This information is shared with social media, sponsorship, analytics, and other vendors or service providers.
See details.

You may click on “Your Choices” below to learn about and use cookie management tools to limit use of cookies when you visit NPR’s sites. You can adjust your cookie choices in those tools at any time. If you click “Agree and Continue” below, you acknowledge that your cookie choices in those tools will be respected and that you otherwise agree to the use of cookies on NPR’s sites.


Eating This One Thing Can Cut Your Cancer Risk in Half, Study Says – Best Life

The food we put into our bodies has the ability to affect our health over time, but it’s not just about cutting harmful foods out of your diet. While it’s true that overdoing it on sweets and fast food can have negative effects, there are also foods you should be eating to keep yourself healthy. In fact, one new study has found that eating a certain food can cut your cancer risk in half. Read on to find out what you should be adding to your diet, and for more ways to monitor your risk, If You Notice This on Your Skin, You Could Be at Risk for 13 Cancers.

Adult man stand at kitchen table and talk on phone. He taste piece of mushroom. Man look down. Colorful vegetables lying on deskAdult man stand at kitchen table and talk on phone. He taste piece of mushroom. Man look down. Colorful vegetables lying on desk

Researchers from Penn State sought to determine the relationship between mushroom consumption and cancer risk, publishing their findings March 16 in the Advances in Nutrition journal. The researchers analyzed more than 19,500 cancer patients by reviewing 17 cancer studies published between 1966 and 2020. According to the new study, people who ate 18 grams of mushrooms every day had a 45 percent lower risk of developing cancer than those who did not eat mushrooms.

“Overall, these findings provide important evidence for the protective effects of mushrooms against cancer,” study co-author John Richie, PhD, a Penn State Cancer Institute researcher and professor of public health sciences and pharmacology, said in a statement. And for things to avoid ingesting, If You Drink This Every Day, Your Heart Could Be in Danger, Study Finds.


When looking at specific cancers, the researchers found that the association between breast cancer and mushroom consumption was the strongest. In fact, people who ate mushrooms daily had a significantly lower risk of developing breast cancer. Study co-author Djibril M. Ba, MPH, a graduate student in epidemiology at Penn State College of Medicine, explained in a statement that this may be because most of the studies they reviewed did not include other specific types of cancer. “Future studies are needed to better pinpoint the mechanisms involved and specific cancers that may be impacted,” Richie explained. And for more useful information delivered straight to your inbox, sign up for our daily newsletter.

Unrecognized woman preparing fresh salad, chopping mushroom, cherry tomato, and lettuce.Unrecognized woman preparing fresh salad, chopping mushroom, cherry tomato, and lettuce.

Mushrooms are full of important vitamins, nutrients, and antioxidants, but the researchers say one antioxidant in particular may explain the cancer risk reduction properties of mushrooms: ergothioneine. “Mushrooms are the highest dietary source of ergothioneine, which is a unique and potent antioxidant and cellular protector,” Ba explained. “Replenishing antioxidants in the body may help protect against oxidative stress and lower the risk of cancer.” And while shiitake, oyster, maitake, and king oyster mushrooms have higher amounts of ergothioneine than white bottom, cremini, and portobello mushrooms, the researchers say that adding any variety of mushrooms into your daily diet will lower your risk of cancer. And for more things to pay attention to when you’re eating, If This Happens When You Eat or Drink, You Need Your Thyroid Checked.

Cooking healthy food. Hands holding champignon mushrooms, flat lay.Cooking healthy food. Hands holding champignon mushrooms, flat lay.

If you’re not willing to reach for 18 grams of mushrooms every day, you might at least consider eating this vegetable once a week. Another study published in 2019 in the International Journal of Cancer found that weekly mushroom consumption can help lower the risk of one specific type of cancer. For this study, researchers examined more than 36,000 men over the span of a decade and found that participants who ate mushrooms at least once or twice a week had an 8 percent lower risk of developing prostate cancer than those who ate mushrooms less than once a week. Even better, those who ate mushrooms three or more times a week had a 17 percent lower risk than those who ate mushrooms less than once a week.

“Considering the average American consumes less than 5 grams of mushrooms per day … one would expect that even a small increase in mushroom consumption to offer potential health benefits,” study lead author Shu Zhang, an assistant professor of epidemiology in the Department of Health Informatics and Public Health at Tohoku University School of Public Health, said in a statement. And for more guidance on healthy eating, Never Eat Leftovers That’ve Been in the Fridge This Long, Experts Warn.